Primer on pramlintide, an amylin analog.
Loading...
Issue Date
2011-05
Authors
Traina, Andrea N ++
Kane, Michael P
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
PURPOSE: Pramlintide is an injectable synthetic analog of human amylin. It is indicated for patients with type 1 or type 2 diabetes who are taking mealtime insulin but have been unable to achieve desired glucose targets. Pramlintide decreases postprandial glucose by lowering inappropriate postmeal glucagon secretion, slowing gastric emptying, and increasing satiety. As such, pramlintide targets several of the defects commonly seen in patients with diabetes. Given the unique characteristics of this agent in the treatment of diabetes, a practical guide to its use is presented.
CONCLUSION: Pramlintide treats diabetes with a novel mechanism of action, offering the potential for improved postprandial control and weight loss for patients with type 1 or type 2 diabetes. Providers and diabetes educators should be familiar with the utility of the medication as well as its potential limitations in order to fully educate patients and maximize treatment options for patients with diabetes.
Citation
Traina AN, Kane MP. Primer on pramlintide, an amylin analog. Diabetes Educ. 2011 May-Jun;37(3):426-31. doi: 10.1177/0145721711403011. Epub 2011 Apr 6. PMID: 21471470.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).